These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28459467)

  • 1. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
    Dai L; Lin Z; Qiao J; Chen Y; Flemington EK; Qin Z
    Oncogene; 2017 Aug; 36(35):5068-5074. PubMed ID: 28459467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
    Shigemi Z; Furukawa Y; Hosokawa K; Minami S; Matsuhiro J; Nakata S; Watanabe T; Kagawa H; Nakagawa K; Takeda H; Fujimuro M
    Int J Oncol; 2016 Jan; 48(1):293-304. PubMed ID: 26647777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.
    Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S
    Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma.
    Dai L; Trillo-Tinoco J; Cao Y; Bonstaff K; Doyle L; Del Valle L; Whitby D; Parsons C; Reiss K; Zabaleta J; Qin Z
    Blood; 2015 Dec; 126(26):2821-31. PubMed ID: 26531163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells.
    He M; Tan B; Vasan K; Yuan H; Cheng F; Ramos da Silva S; Lu C; Gao SJ
    J Pathol; 2017 Jul; 242(3):309-321. PubMed ID: 28393364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.
    Kariya R; Taura M; Suzu S; Kai H; Katano H; Okada S
    Cancer Lett; 2014 Jan; 342(1):52-9. PubMed ID: 24012878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
    Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES
    Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.
    Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z
    Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
    Li J; Zheng LM; King I; Doyle TW; Chen SH
    Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
    Ueno M; Kariya R; Sittithumcharee G; Okada S
    Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo.
    Towata T; Komizu Y; Suzu S; Matsumoto Y; Ueoka R; Okada S
    Leuk Res; 2010 Jul; 34(7):906-11. PubMed ID: 20074798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma.
    Chen J; Goyal N; Dai L; Lin Z; Del Valle L; Zabaleta J; Liu J; Post SR; Foroozesh M; Qin Z
    Blood; 2020 Nov; 136(19):2175-2187. PubMed ID: 32518949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.
    Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC
    Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
    Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diethyldithiocarbamate induces apoptosis in HHV-8-infected primary effusion lymphoma cells via inhibition of the NF-κB pathway.
    Matsuno T; Kariya R; Yano S; Morino-Koga S; Taura M; Suico MA; Shimauchi Y; Matsuyama S; Okamoto Y; Shuto T; Kai H; Okada S
    Int J Oncol; 2012 Apr; 40(4):1071-8. PubMed ID: 22200846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer activities of parthenolide in primary effusion lymphoma preclinical models.
    Karam L; Abou Staiteieh S; Chaaban R; Hayar B; Ismail B; Neipel F; Darwiche N; Abou Merhi R
    Mol Carcinog; 2021 Aug; 60(8):567-581. PubMed ID: 34101920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.